http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20210043011-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4491771775a6852122ade89ca60a013c |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70503 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6883 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1774 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6872 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P9-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-095 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6883 |
| filingDate | 2017-09-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea3e5b902128f26cffaffd665141904d |
| publicationDate | 2021-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20210043011-A |
| titleOfInvention | Use of recombinant lymphocyte activation gene-3 |
| abstract | An object of the present invention is a novel strategy capable of evaluating the mortality and mortality risk due to cardiovascular disease, other chronic inflammatory diseases, cardiovascular and non-cardiovascular diseases based on the lymphocyte activating gene 3 (LAG3) protein deficiency, and recombinant human lymphocytes as a companion treatment It is to provide a method for mediating this risk with a tailored treatment regimen comprising the use of activating gene-3. In one embodiment, the method comprises a first step of qualitatively preliminary screening a subject for one or more risk factors for developing cardiovascular disease, a second step of quantitatively detecting LAG3 protein deficiency in a sample from the subject, and an anti-inflammatory agent. , HDL-C function, agents that improve size and/or inadequate HDL-C reduce agents, PCSK9 inhibitors (a new class of drugs that significantly lower LDL cholesterol levels) or other cholesterol-lowering biology, cholesterol changes, small molecules, drugs MHC Drugs that mimic LAG3 function by binding to class II molecules, drugs that mimic the effect of LAG3 phosphorylation signaling, drugs MHC that mimic the role of LAG3 in CD4 +, CD8 + T, NK cells, monocytes, dendritic cells, B regs and Tregs There is a third step of treating a subject with recombinant human lymphocyte activating gene-3 as a co-treatment for one or more agents selected from the group consisting of a composition comprising a class II molecule and a substance that mimics the role of LAG3 in a lipid raft of a cell membrane. . The LAG3 parent includes agents that modulate intracellular cations such as potassium, sodium, lithium and calcium, including small molecule agents that affect the structure or flexibility of DNA or RNA that affects the regulation of LAG3 transcription, micro RNAs, oligonucleotides, and biological agents. , Activating antibodies may be included. |
| priorityDate | 2015-09-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 400.